We are live on ! Find out more
NRXP icon

NRX Pharmaceuticals

2.55 USD
-0.25
8.93%
At close Updated Nov 19, 4:00 PM EST
Pre-market
After hours
2.55
0.00
0%
1 day
-8.93%
5 days
13.33%
1 month
-3.04%
3 months
-23.42%
6 months
-15.84%
Year to date
-2.67%
1 year
19.72%
5 years
-95.03%
10 years
-97.34%
 

About: NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

Employees: 29

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 11.1%
Neutral 83.3%
Negative 5.6%
Neutral
Seeking Alpha
2 days ago
NRx Pharmaceuticals, Inc. (NRXP) Q3 2026 Earnings Call Transcript
NRx Pharmaceuticals, Inc. ( NRXP ) Q3 2026 Earnings Call November 17, 2026 8:00 AM EST Company Participants Jonathan Javitt - Co-Founder, Chairman & CEO Michael Abrams - CFO & Treasurer Conference Call Participants Brian Korb Elemer Piros - Lucid Capital Markets, LLC, Research Division Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division Thomas Shrader - BTIG, LLC, Research Division Edward Woo - Ascendiant Capital Markets LLC, Research Division Presentation Operator Good day, ladies and gentlemen, and welcome to the NRx Pharmaceuticals Third Quarter 2026 Results Conference Call.
NRx Pharmaceuticals, Inc. (NRXP) Q3 2026 Earnings Call Transcript
Neutral
MarketBeat
2 days ago
What NRx Pharmaceuticals (NRXP) Said on Its Q3 Earnings Call
NRx Pharmaceuticals NASDAQ: NRXP reported higher third-quarter patient revenue and a narrower net loss, while outlining plans to commercialize its first approved drug and advance experimental treatments for depression and other conditions.
What NRx Pharmaceuticals (NRXP) Said on Its Q3 Earnings Call
Neutral
GlobeNewsWire
2 days ago
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Third Quarter 2026 Financial Results and Provides Corporate Update
FDA approved the Company's first drug, preservative-free ketamine, ahead of its GDUFA goal date; commercial launch underway with a 17-person sales force
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Negative
Zacks Investment Research
3 days ago
NRx Pharmaceuticals, Inc. (NRXP) Reports Q3 Loss, Misses Revenue Estimates
NRx Pharmaceuticals, Inc. (NRXP) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.18 per share a year ago.
NRx Pharmaceuticals, Inc. (NRXP) Reports Q3 Loss, Misses Revenue Estimates
Neutral
GlobeNewsWire
7 days ago
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2026 Financial Results and Provide Corporate Update
WILMINGTON, Del., Nov. 12, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a commercial biopharmaceutical company developing medicines that target depression, PTSD and suicidality, today announced that it will release its third quarter 2026 financial results before the market opens on Tuesday, November 17, 2026 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/.
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2026 Financial Results and Provide Corporate Update
Neutral
GlobeNewsWire
8 days ago
NRx Pharmaceuticals Begins Selling U.S.-Made, Preservative-Free Ketamine Amid Long-Running Shortage
WILMINGTON, Del., Nov. 11, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a commercial biopharmaceutical company developing medicines that target depression, PTSD and suicidality, today announced that it commenced selling its newly approved preservative-free ketamine providing a guaranteed, U.S.-manufactured supply of a drug listed as in shortage since 2018.
NRx Pharmaceuticals Begins Selling U.S.-Made, Preservative-Free Ketamine Amid Long-Running Shortage
Neutral
Seeking Alpha
20 days ago
NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA Approval of Preservative-Free Ketamine Transcript
NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA Approval of Preservative-Free Ketamine Transcript
NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA Approval of Preservative-Free Ketamine Transcript
Positive
MarketBeat
20 days ago
NRx Pharmaceuticals Wins FDA Approval for Preservative-Free Ketamine Injection
NRx Pharmaceuticals NASDAQ: NRXP said the U.S. Food and Drug Administration approved its abbreviated new drug application for preservative-free ketamine injection, marking the company's first approved product and its transition from a development-stage company to a commercial pharmaceutical company.
NRx Pharmaceuticals Wins FDA Approval for Preservative-Free Ketamine Injection
Neutral
GlobeNewsWire
20 days ago
NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date
WILMINGTON, Del., Oct. 30, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a commercial biopharmaceutical company developing medicines that target depression, PTSD, and suicidality today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Abbreviated New Drug Application (ANDA) for Preservative-Free Ketamine. The approval comes ahead of the FDA-announced November 10, approval goal date.
NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date
Neutral
GlobeNewsWire
21 days ago
NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine
Company to issue press release before market open; conference call to follow at 8:30 a.m. ET Company to issue press release before market open; conference call to follow at 8:30 a.m. ET
NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine
Price charts implemented using Lightweight Charts™